Skip to main content

Advertisement

SpringerLink
Log in

Increased incidence of papillary thyroid microcarcinoma with decreased tumor size of thyroid cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The prevalence of papillary thyroid microcarcinoma (PTMC) in thyroid cancer varies from 20.0% to 42.8% with a mean of 30.0%. Most of these patients have benign clinical courses and receive less aggressive therapeutic procedures in most medical centers. This study retrospectively reviewed 30 years data in one institute and compared it with recent publications to illustrate change in trends and influence of PTMC. Incidental PTMC is usually diagnosed as a postoperative microcarcinoma following thyroidectomy for presumably benign thyroid lesions. Subtotal thyroidectomy or lobectomy without radioactive iodide treatment is sufficient to treat incidental PTMC. In contrast, aggressive surgical treatment with 131I therapy is indicated for non-incidental PTMC. Those with PTMC in the absence of extra-thyroid invasion diagnosed by postoperative permanent section received follow-up if they had initially received subtotal thyroidectomy. In long-term follow-up studies, cancer-specific mortality for PTMC ranged from 0% to 4%. Most of the mortality cases had distant metastasis at the time of surgery. The clinical course and therapeutic strategies for the non-incidental PTMC patients depend on the TNM stage at the time of diagnosis. One-third of PTMC with clinically aggressive behavior cannot be treated as indolent disease. Invasive tumor markers or larger tumor size are useful to predict tumor recurrence or distant metastasis for PTMC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Heckman CA, et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 2008;68:4754–62. doi:10.1158/0008-5472.CAN-07-5809.

    Article  PubMed  CAS  Google Scholar 

  2. Tammela T, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008;454:656–60. doi:10.1038/nature07083.

    Article  PubMed  CAS  Google Scholar 

  3. Gerard AC, et al. Relationships between cell division, expression of growth factors and microcirculation in the thyroids of Tg-A2aR transgenic mice and patients with Graves’ disease. J Endocrinol. 2003;177:269–77. doi:10.1677/joe.0.1770269.

    Article  PubMed  CAS  Google Scholar 

  4. Poulaki V, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. J Clin Endocrinol Metab. 2003;88:5392–8. doi:10.1210/jc.2003-030389.

    Article  PubMed  CAS  Google Scholar 

  5. Lin JD. Papillary thyroid carcinoma with lymph node metastases. Growth Factors. 2007;25:41–9. doi:10.1080/08977190601000095.

    Article  PubMed  CAS  Google Scholar 

  6. Howlett DC, Speirs A. The thyroid incidentaloma—ignore or investigate? J Ultrasound Med. 2007;26:1367–71.

    PubMed  Google Scholar 

  7. Phitayakorn R, McHenry CR. Incidental thyroid carcinoma in patients with Graves’ disease. Am J Surg. 2008;195:292–7. doi:10.1016/j.amjsurg.2007.12.006.

    Article  PubMed  Google Scholar 

  8. Mazeh H, Divino C, Nagi C, Bleiweiss IJ, Weber K. Incidental metastatic microcarcinoma of the thyroid identified after total parathyroidectomy. Thyroid. 2007;17:685–7. doi:10.1089/thy.2006.0295.

    Article  PubMed  Google Scholar 

  9. de Matos PS, Ferreira AP, Ward LS. Prevalence of papillary microcarcinoma of the thyroid in Brazilian autopsy and surgical series. Endocr Pathol. 2006;17:165–73. doi:10.1385/EP:17:2:165.

    Article  PubMed  Google Scholar 

  10. Sobin LH, UICC. In: Wittekind Ch, editor. TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002. p. 52–6.

    Google Scholar 

  11. Rosário PW, et al. Is adjuvant therapy useful in patients with papillary carcinoma smaller than 2 cm? Thyroid. 2007;17:1225–8. doi:10.1089/thy.2006.0254.

    Article  PubMed  Google Scholar 

  12. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007;245:366–78. doi:10.1097/01.sla.0000250445.92336.2a.

    Article  PubMed  Google Scholar 

  13. Döbert N, Menzel C, Oeschger S, Grünwald F. Differentiated thyroid carcinoma: the new UICC 6th edition TNM classification system in a retrospective analysis of 169 patients. Thyroid. 2004;14:65–70. doi:10.1089/105072504322783867.

    Article  PubMed  Google Scholar 

  14. Rossi R, et al. Differentiated thyroid cancers 11–20 mm in diameter have clinical and histopathologic characteristics suggesting higher aggressiveness than those < or = 10 mm. Thyroid. 2008;18:309–15. doi:10.1089/thy.2007.0100.

    Article  PubMed  Google Scholar 

  15. Lin JD, et al. Operative strategy for follicular thyroid cancer in risk groups stratified by pTNM staging. Surg Oncol. 2007;16:107–13. doi:10.1016/j.suronc.2007.05.004.

    Article  PubMed  Google Scholar 

  16. Delellis RA, Lloyd RV, Heitx PU, et al. Pathology and genetics of tumors of endocrine organs. In: World Health Organization of tumours. IARC, Lyon; 2004. pp. 73–6.

  17. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414–24.

    Article  PubMed  CAS  Google Scholar 

  18. Deveci MS, Deveci G, LiVolsi VA, Gupta PK, Baloch ZW. Concordance between thyroid nodule sizes measured by ultrasound and gross pathology examination: effect on patient management. Diagn Cytopathol. 2007;35:579–83. doi:10.1002/dc.20714.

    Article  PubMed  Google Scholar 

  19. Baloch ZW, LiVolsi VA. Microcarcinoma of the thyroid. Adv Anat Pathol. 2006;13:69–75. doi:10.1097/01.pap.0000213006.10362.17.

    Article  PubMed  Google Scholar 

  20. Lissak B, Vannetzel JM, Gallouedec N, Berrod JL, Rieu M. Solitary skin metastasis as the presenting feature of differentiated thyroid microcarcinoma: report of two cases. J Endocrinol Invest. 1995;18:813–6.

    PubMed  CAS  Google Scholar 

  21. Russo F, et al. Clinico-pathological study of microcarcinoma of the thyroid. Minerva Chir. 1997;52:891–900.

    PubMed  CAS  Google Scholar 

  22. Kwak JY, et al. Extrathyroid extension of well-differentiated papillary thyroid microcarcinoma on US. Thyroid. 2008;18:609–14. doi:10.1089/thy.2007.0345.

    Article  PubMed  Google Scholar 

  23. Lin JD, Kuo SF, Chao TC, Hsueh C. Incidental and nonincidental papillary thyroid microcarcinoma. Ann Surg Oncol. 2008;15:2287–92. doi:10.1245/s10434-008-9958-2.

    Article  PubMed  Google Scholar 

  24. Noguchi S, Yamashita H, Uchino S, Watanabe S. Papillary microcarcinoma. World J Surg. 2008;32:747–53. doi:10.1007/s00268-007-9453-0.

    Article  PubMed  Google Scholar 

  25. Pelizzo MR, et al. Papillary thyroid microcarcinoma (PTMC): prognostic factors, management and outcome in 403 patients. Eur J Surg Oncol. 2006;32:1144–8. doi:10.1016/j.ejso.2006.07.001.

    Article  PubMed  CAS  Google Scholar 

  26. Roti E, et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab. 2006;91:2043–6. doi:10.1210/jc.2005-2372.

    Article  CAS  Google Scholar 

  27. Hay ID, et al. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery. 1992;112:1139–46.

    PubMed  CAS  Google Scholar 

  28. Rodriguez JM, et al. Papillary thyroid microcarcinoma: clinical study and prognosis. Eur J Surg. 1997;163:255–9.

    PubMed  CAS  Google Scholar 

  29. Chow SM, et al. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98:31–40. doi:10.1002/cncr.11442.

    Article  PubMed  Google Scholar 

  30. Baudin E, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer. 1998;83:553–9. doi:10.1002/(SICI)1097-0142(19980801)83:3<553::AID-CNCR25>3.0.CO;2-U.

    Article  PubMed  CAS  Google Scholar 

  31. Mansberg R, Son H, Kean AM. Occult carcinoma of the thyroid presenting with orbital metastasis. Clin Nucl Med. 2006;31:109–11. doi:10.1097/01.rlu.0000196605.16989.ef.

    Article  PubMed  Google Scholar 

  32. Kini S, et al. Occult medullary carcinoma of thyroid with lymph node metastases: a case report. Acta Cytol. 2008;52:105–8.

    PubMed  Google Scholar 

  33. Hubert JP Jr, Kiernan PD, Beahrs OH, McConahey WM, Woolner LB. Occult papillary carcinoma of the thyroid. Arch Surg. 1980;115:394–8.

    PubMed  Google Scholar 

  34. Silliphant WM, Klinck GH, Levitin MS. Thyroid cancer and death. A clinicopathological study of 193 autopsies. Cancer. 1964;17:513–25. doi:10.1002/1097-0142(196404)17:4<513::AID-CNCR2820170413>3.0.CO;2-2.

    Article  PubMed  CAS  Google Scholar 

  35. Silverberg SG, Vidone RA. Carcinoma of the thyroid in surgical and postmortem material. Analysis of 300 cases at autopsy and literature review. Ann Surg. 1966;164:291–9.

    Article  PubMed  CAS  Google Scholar 

  36. Sampson RJ, Key CR, Buncher CR, Iijima S. Thyroid carcinoma in Hiroshima and Nagasaki. I. Prevalence of thyroid carcinoma at autopsy. JAMA. 1969;209:65–70. doi:10.1001/jama.209.1.65.

    Article  PubMed  CAS  Google Scholar 

  37. Sampson RJ, Woolner LB, Bahn RC, Kurland LT. Occult thyroid carcinoma in Olmsted County, Minnesota: prevalence at autopsy compared with that in Hiroshima and Nagasaki, Japan. Cancer. 1974;34:2072–6. doi:10.1002/1097-0142(197412)34:6<2072::AID-CNCR2820340629>3.0.CO;2-#.

    Article  PubMed  CAS  Google Scholar 

  38. Franssila KO, Harach HR. Occult papillary carcinoma of the thyroid in children and young adults. A systemic autopsy study in Finland. Cancer. 1986;58:715–9. doi:10.1002/1097-0142(19860801)58:3<715::AID-CNCR2820580319>3.0.CO;2-P.

    Article  PubMed  CAS  Google Scholar 

  39. Ottino A, Pianzola HM, Castelletto RH. Occult papillary thyroid carcinoma at autopsy in La Plata, Argentina. Cancer. 1989;64:547–51. doi:10.1002/1097-0142(19890715)64:2<547::AID-CNCR2820640232>3.0.CO;2-N.

    Article  PubMed  CAS  Google Scholar 

  40. Bisi H, et al. The prevalence of unsuspected thyroid pathology in 300 sequential autopsies, with special reference to the incidental carcinoma. Cancer. 1989;64:1888–93. doi:10.1002/1097-0142(19891101)64:9<1888::AID-CNCR2820640922>3.0.CO;2-C.

    Article  PubMed  CAS  Google Scholar 

  41. Autelitano F, Spagnoli LG, Santeusanio G, Villaschi S, Autelitano M. Occult carcinoma of the thyroid gland: an epidemiological study of autopsy material. Ann Ital Chir. 1990;61:141–6.

    PubMed  CAS  Google Scholar 

  42. Yamamoto Y, Maeda T, Izumi K, Otsuka H. Occult papillary carcinoma of the thyroid. A study of 408 autopsy cases. Cancer. 1990;65:1173–9. doi:10.1002/1097-0142(19900301)65:5<1173::AID-CNCR2820650524>3.0.CO;2-2.

    Article  PubMed  CAS  Google Scholar 

  43. Martinez-Tello FJ, Martinez-Cabruja R, Fernandez-Martin J, Lasso-Oria C, Ballestin-Carcavilla C. Occult carcinoma of the thyroid. A systematic autopsy study from Spain of two series performed with two different methods. Cancer. 1993;71:4022–9. doi:10.1002/1097-0142(19930615)71:12<4022::AID-CNCR2820711236>3.0.CO;2-O.

    Article  PubMed  CAS  Google Scholar 

  44. Furmanchuk AW, Roussak N, Ruchti C. Occult thyroid carcinomas in the region of Minsk, Belarus. An autopsy study of 215 patients. Histopathology. 1993;23:319–25. doi:10.1111/j.1365-2559.1993.tb01214.x.

    Article  PubMed  CAS  Google Scholar 

  45. Avetisian IL, Petrova GV. Latent thyroid pathology in residents of Kiev, Ukraine. J Environ Pathol Toxicol Oncol. 1996;15:239–43.

    PubMed  CAS  Google Scholar 

  46. Mitselou A, Vougiouklakis T, Peschos D, Dallas P, Agnantis NJ. Occult thyroid carcinoma. A study of 160 autopsy cases. The first report for the region of Epirus-Greece. Anticancer Res. 2002;22:427–32.

    PubMed  Google Scholar 

  47. Solares CA, Penalonzo MA, Xu M, Orellana E. Occult papillary thyroid carcinoma in postmortem species: prevalence at autopsy. Am J Otolarygol. 2005;26:87–90. doi:10.1016/j.amjoto.2004.08.003.

    Article  Google Scholar 

  48. Jank S, et al. The diagnostic value of ultrasonography to detect occult lymph node involvement at different levels in patients with squamous cell carcinoma in the maxillofacial region. Int J Oral Maxillofac Surg. 2003;32:39–42. doi:10.1054/ijom.2002.0326.

    Article  PubMed  CAS  Google Scholar 

  49. King DL, Stack BC Jr, Spring PM, Walker R, Bodenner DL. Incidence of thyroid carcinoma in fluorodeoxyglucose positron emission tomography-positive thyroid incidentalomas. Otolaryngol Head Neck Surg. 2007;137:400–4. doi:10.1016/j.otohns.2007.02.037.

    Article  PubMed  Google Scholar 

  50. Lin KD, et al. Clinical presentations and predictive variables of thyroid microcarcinoma with distant metastasis. Int Surg. 1997;82:378–81.

    PubMed  CAS  Google Scholar 

  51. Besic N, Pilko G, Petric R, Hocevar M, Zgajnar J. Papillary thyroid microcarcinoma: prognostic factors and treatment. J Surg Oncol. 2008;97:221–5. doi:10.1002/jso.20935.

    Article  PubMed  Google Scholar 

  52. Batistatou A, et al. Differential expression of dysadherin in papillary thyroid carcinoma and microcarcinoma: correlation with E-cadherin. Endocr Pathol. 2008;19:197–202. doi:10.1007/s12022-008-9035-1.

    Article  PubMed  Google Scholar 

  53. Cvejic D, et al. Apoptosis and proliferation related molecules (Bcl-2, Bax, p53, PCNA) in papillary microcarcinoma versus papillary carcinoma of the thyroid. Pathology. 2008;40:475–80. doi:10.1080/00313020802026989.

    Article  PubMed  CAS  Google Scholar 

  54. Antonaci A, et al. Survivin and cyclin D1 are jointly expressed in thyroid papillary carcinoma and microcarcinoma. Oncol Rep. 2008;20:63–7.

    PubMed  Google Scholar 

  55. Min HS, et al. S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid. Mod Pathol. 2008;21:748–55. doi:10.1038/modpathol.2008.51.

    Article  PubMed  CAS  Google Scholar 

  56. Lim DJ, et al. Clinical, histopathological, and molecular characteristics of papillary thyroid microcarcinoma. Thyroid. 2007;17:883–8. doi:10.1089/thy.2007.0001.

    Article  PubMed  CAS  Google Scholar 

  57. Londero SC, et al. Papillary microcarcinoma of the thyroid gland: is the immunohistochemical expression of cyclin D1 or galectin-3 in primary tumour an indicator of metastatic disease? Acta Oncol. 2008;47:451–7. doi:10.1080/02841860701630242.

    Article  PubMed  CAS  Google Scholar 

  58. Khoo ML, Ezzat S, Freeman JL, Asa SL. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab. 2002;87:1810–3. doi:10.1210/jc.87.4.1810.

    Article  PubMed  CAS  Google Scholar 

  59. Pestell RG, et al. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev. 1999;20:501–34. doi:10.1210/er.20.4.501.

    Article  PubMed  CAS  Google Scholar 

  60. Lim YC, Choi EC, Yoon YH, Kim EH, Koo BS. Central lymph node metastases in unilateral papillary thyroid microcarcinoma. Br J Surg. 2009;96:253–7. doi:10.1002/bjs.6484.

    Article  PubMed  CAS  Google Scholar 

  61. Sugitani I, Fujimoto Y. Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. Endocr J. 1999;46:209–16. doi:10.1507/endocrj.46.209.

    Article  PubMed  CAS  Google Scholar 

  62. Pisanu A, Reccia I, Nardello O, Uccheddu A. Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors. World J Surg. 2009;33:460–8. doi:10.1007/s00268-008-9870-8.

    Article  PubMed  Google Scholar 

  63. Jovanovic L, Delahunt B, McIver B, Eberhardt NL, Grebe SK. Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone. J Pathol. 2008;215:145–54. doi:10.1002/path.2342.

    Article  PubMed  CAS  Google Scholar 

  64. Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab. 1998;83:4116–22. doi:10.1210/jc.83.11.4116.

    Article  PubMed  CAS  Google Scholar 

  65. Lin X, Finklestein S, Zhu B, Silverman J. Molecular analysis of multifocal papillary thyroid carcinoma. J Mol Endocrinol. 2008;41:195–203. doi:10.1677/JME-08-0063.

    Article  PubMed  CAS  Google Scholar 

  66. Biscolla RP, et al. Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. Thyroid. 2004;14:946–52. doi:10.1089/thy.2004.14.946.

    Article  PubMed  Google Scholar 

  67. Cupisti K, et al. Synchronous occurrence of a follicular, papillary and medullary thyroid carcinoma in a recurrent goiter. Endocr J. 2005;52:281–5. doi:10.1507/endocrj.52.281.

    Article  PubMed  Google Scholar 

  68. Behrand M, von Wasielewski R, Brabant G. Simultaneous medullary and papillary microcarcinoma of thyroid in a patient with secondary hyperparathyroidism. Endocr Pathol. 2002;13:65–73. doi:10.1385/EP:13:1:65.

    Article  PubMed  Google Scholar 

  69. Satge D, Grob JC, Pusel J, Methlin G. Thyroid microcarcinoma with a fatal outcome and 34 other unusually aggressive cases reported in the literature. Arch Anat Cytol Pathol. 1990;38:143–51.

    PubMed  CAS  Google Scholar 

  70. Yamashita H, et al. Extracapsular invasion of lymph node metastasis. A good indicator of disease recurrence and poor prognosis in patients with thyroid microcarcinoma. Cancer. 1999;86:842–9. doi:10.1002/(SICI)1097-0142(19990901)86:5<842::AID-CNCR21>3.0.CO;2-X.

    Article  PubMed  CAS  Google Scholar 

  71. Ito Y, et al. Papillary microcarcinoma of the thyroid: how should it be treated? World J Surg. 2004;28:1115–21. doi:10.1007/s00268-004-7644-5.

    Article  PubMed  Google Scholar 

  72. Lupoli G, et al. Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet. 1999;353:637–9. doi:10.1016/S0140-6736(98)08004-0.

    Article  PubMed  CAS  Google Scholar 

  73. Avetisian IL, Gulchiy NV, Demidiuk AP, Stashuk AV. Thyroid pathology in residents of the Kiev region, Ukraine, during pre- and post-Chernobyl periods. J Environ Pathol Toxicol Oncol. 1996;15:233–7.

    PubMed  CAS  Google Scholar 

  74. Furlan JC, Rosen IB. Prognostic relevance of previous exposure to ionizing radiation in well-differentiated thyroid cancer. Langenbecks Arch Surg. 2004;389:198–203. doi:10.1007/s00423-003-0424-0.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, 5, Fu-Shin St. Kweishan County, Taoyuan Hsien, Taiwan, R.O.C

    Jen-Der Lin

Authors
  1. Jen-Der Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jen-Der Lin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lin, JD. Increased incidence of papillary thyroid microcarcinoma with decreased tumor size of thyroid cancer. Med Oncol 27, 510–518 (2010). https://doi.org/10.1007/s12032-009-9242-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-009-9242-8

Keywords

Search

Navigation